Frazier Life Sciences XI, L.P.
SEC Form 4 insider trading activity
Frazier Life Sciences XI, L.P. has filed 1 SEC Form 4 filing (5 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Aug 6, 2026.
On the most recent filing, Frazier Life Sciences XI, L.P. is listed as 10% Owner at Attovia Therapeutics, Inc. Inside the rolling window, Frazier Life Sciences XI, L.P. reported 1 open-market purchase totaling $10.0M in ATTO and no open-market sales.
Companies traded
Other insiders at ATTO
Insider Buying
$10.0M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Frazier Life Sciences XI, L.P. made?
Frazier Life Sciences XI, L.P. has filed 1 SEC Form 4 filing (5 transaction rows) across 1 company since 2026.
Which companies does Frazier Life Sciences XI, L.P. trade?
Frazier Life Sciences XI, L.P. has filed SEC Form 4 disclosures for 1 company, including ATTO.
When was Frazier Life Sciences XI, L.P.'s most recent SEC Form 4 filing?
Frazier Life Sciences XI, L.P.'s most recent SEC Form 4 filing on Tracefour is dated Aug 6, 2026.
What is Frazier Life Sciences XI, L.P.'s total buy and sell value in the current window?
Inside the rolling retention window, Frazier Life Sciences XI, L.P. bought $10.0M and sold $0 based on SEC Form 4 filings.
What was Frazier Life Sciences XI, L.P.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 588,235 ATTO shares on 2026-08-06, worth $10.0M, per SEC Form 4 filings.